C
Amphastar Pharmaceuticals, Inc.
AMPH
$28.81
$0.491.73%
C
Hold
11/26/2024Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C from C+ on 11/26/2024 due to a decline in the growth index, valuation index and total return index. Operating cash flow declined 13.24% from $69.11M to $59.96M.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C from C+ on 11/26/2024 due to a decline in the growth index, valuation index and total return index. Operating cash flow declined 13.24% from $69.11M to $59.96M.
C
Hold
9/9/2024Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C+ from C on 9/9/2024 due to an increase in the total return index, solvency index and growth index. The quick ratio increased from 1.68 to 2.55, operating cash flow increased 24.99% from $55.29M to $69.11M, and EBIT increased 15.01% from $48.01M to $55.22M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C+ from C on 9/9/2024 due to an increase in the total return index, solvency index and growth index. The quick ratio increased from 1.68 to 2.55, operating cash flow increased 24.99% from $55.29M to $69.11M, and EBIT increased 15.01% from $48.01M to $55.22M.
C
Hold
6/24/2024Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C from C+ on 6/24/2024 due to a decline in the total return index, volatility index and solvency index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C from C+ on 6/24/2024 due to a decline in the total return index, volatility index and solvency index.
C
Hold
4/12/2024Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C+ from B- on 4/12/2024 due to a noticeable decline in the total return index, volatility index and solvency index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C+ from B- on 4/12/2024 due to a noticeable decline in the total return index, volatility index and solvency index.
B
Buy
3/1/2024Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 3/1/2024 due to a large decline in the total return index, growth index and solvency index. Operating cash flow declined 62.91% from $64.33M to $23.86M, EBIT declined 25.73% from $72.68M to $53.98M, and earnings per share declined from $0.91 to $0.69.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 3/1/2024 due to a large decline in the total return index, growth index and solvency index. Operating cash flow declined 62.91% from $64.33M to $23.86M, EBIT declined 25.73% from $72.68M to $53.98M, and earnings per share declined from $0.91 to $0.69.
B
Buy
2/20/2024Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 2/20/2024 due to a large increase in the total return index, solvency index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 2/20/2024 due to a large increase in the total return index, solvency index and volatility index.
B
Buy
2/5/2024Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 2/5/2024 due to a decline in the total return index, solvency index and efficiency index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 2/5/2024 due to a decline in the total return index, solvency index and efficiency index.
B
Buy
1/19/2024Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 1/19/2024 due to a noticeable increase in the growth index, valuation index and total return index. Earnings per share increased from $0.49 to $0.91, EBIT increased 83.55% from $39.6M to $72.68M, and total revenue increased 23.91% from $145.71M to $180.56M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 1/19/2024 due to a noticeable increase in the growth index, valuation index and total return index. Earnings per share increased from $0.49 to $0.91, EBIT increased 83.55% from $39.6M to $72.68M, and total revenue increased 23.91% from $145.71M to $180.56M.
B
Buy
10/30/2023Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 10/30/2023 due to a large decline in the total return index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 10/30/2023 due to a large decline in the total return index.
B
Buy
8/10/2023Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 8/10/2023 due to a noticeable increase in the growth index, valuation index and volatility index. Operating cash flow increased 36.01% from $40.38M to $54.92M, EBIT increased 10.36% from $33.43M to $36.9M, and total revenue increased 4.06% from $140.02M to $145.71M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 8/10/2023 due to a noticeable increase in the growth index, valuation index and volatility index. Operating cash flow increased 36.01% from $40.38M to $54.92M, EBIT increased 10.36% from $33.43M to $36.9M, and total revenue increased 4.06% from $140.02M to $145.71M.
B
Buy
8/1/2023Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 8/1/2023 due to a decline in the efficiency index, valuation index and total return index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 8/1/2023 due to a decline in the efficiency index, valuation index and total return index.
B
Buy
7/5/2023Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 7/5/2023 due to an increase in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 7/5/2023 due to an increase in the total return index and volatility index.
B
Buy
5/16/2023Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 5/16/2023 due to a decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.6539 to $0.5, net income declined 23.24% from $33.91M to $26.03M, and EBIT declined 11.63% from $37.83M to $33.43M.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 5/16/2023 due to a decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.6539 to $0.5, net income declined 23.24% from $33.91M to $26.03M, and EBIT declined 11.63% from $37.83M to $33.43M.
B
Buy
3/8/2023Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 3/8/2023 due to a large increase in the total return index, growth index and efficiency index. Earnings per share increased from $0.3 to $0.6539, net income increased 113.64% from $15.87M to $33.91M, and EBIT increased 62.87% from $23.23M to $37.83M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 3/8/2023 due to a large increase in the total return index, growth index and efficiency index. Earnings per share increased from $0.3 to $0.6539, net income increased 113.64% from $15.87M to $33.91M, and EBIT increased 62.87% from $23.23M to $37.83M.
B
Buy
2/27/2023Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B- from C+ on 2/27/2023 due to a noticeable increase in the total return index, solvency index and growth index. Operating cash flow increased 623.8% from $2.82M to $20.38M, debt to equity declined from 0.16 to 0.15, and the quick ratio increased from 2.61 to 2.67.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B- from C+ on 2/27/2023 due to a noticeable increase in the total return index, solvency index and growth index. Operating cash flow increased 623.8% from $2.82M to $20.38M, debt to equity declined from 0.16 to 0.15, and the quick ratio increased from 2.61 to 2.67.
C
Hold
10/20/2022Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C+ from B- on 10/20/2022 due to a major decline in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C+ from B- on 10/20/2022 due to a major decline in the total return index and volatility index.
B
Buy
8/12/2022Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 8/12/2022 due to a decline in the growth index, total return index and efficiency index. Operating cash flow declined 94.45% from $50.77M to $2.82M, earnings per share declined from $0.47 to $0.33, and net income declined 28.48% from $24.25M to $17.35M.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 8/12/2022 due to a decline in the growth index, total return index and efficiency index. Operating cash flow declined 94.45% from $50.77M to $2.82M, earnings per share declined from $0.47 to $0.33, and net income declined 28.48% from $24.25M to $17.35M.
B
Buy
7/11/2022Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 7/11/2022 due to an increase in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 7/11/2022 due to an increase in the total return index and volatility index.
B
Buy
6/21/2022Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 6/21/2022 due to a decline in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to B- from B on 6/21/2022 due to a decline in the total return index and volatility index.
B
Buy
3/15/2022Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 3/15/2022 due to a significant increase in the total return index, efficiency index and valuation index. Total capital increased 2.59% from $536.31M to $550.19M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B from B- on 3/15/2022 due to a significant increase in the total return index, efficiency index and valuation index. Total capital increased 2.59% from $536.31M to $550.19M.
B
Buy
12/14/2021Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B- from C+ on 12/14/2021 due to a noticeable increase in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to B- from C+ on 12/14/2021 due to a noticeable increase in the total return index and volatility index.
C
Hold
12/1/2021Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C+ from C on 12/1/2021 due to a significant increase in the valuation index, volatility index and efficiency index. Net income increased 280.43% from $7.77M to $29.55M, and total capital increased 0.52% from $533.55M to $536.31M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C+ from C on 12/1/2021 due to a significant increase in the valuation index, volatility index and efficiency index. Net income increased 280.43% from $7.77M to $29.55M, and total capital increased 0.52% from $533.55M to $536.31M.
C
Hold
6/16/2021Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 6/16/2021 due to an increase in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 6/16/2021 due to an increase in the total return index and volatility index.
C
Hold
5/11/2021Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D on 5/11/2021 due to a significant increase in the growth index and efficiency index. EBIT increased 257.97% from $2.88M to $10.31M, net income increased 180.36% from -$6.27M to $5.04M, and earnings per share increased from -$0.1338 to $0.1.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D on 5/11/2021 due to a significant increase in the growth index and efficiency index. EBIT increased 257.97% from $2.88M to $10.31M, net income increased 180.36% from -$6.27M to $5.04M, and earnings per share increased from -$0.1338 to $0.1.
D
Sell
3/16/2021Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D from C- on 3/16/2021 due to a significant decline in the growth index, volatility index and efficiency index. Earnings per share declined from $0.08 to -$0.1321, net income declined 260.07% from $3.92M to -$6.27M, and EBIT declined 157.46% from $3.52M to -$2.02M.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D from C- on 3/16/2021 due to a significant decline in the growth index, volatility index and efficiency index. Earnings per share declined from $0.08 to -$0.1321, net income declined 260.07% from $3.92M to -$6.27M, and EBIT declined 157.46% from $3.52M to -$2.02M.
C
Hold
11/12/2020Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 11/12/2020 due to a significant increase in the growth index, efficiency index and valuation index. Net income increased 2,141.15% from -$192 to $3.92M, earnings per share increased from -$0.0041 to $0.08, and EBIT increased 220.36% from -$2.92M to $3.52M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 11/12/2020 due to a significant increase in the growth index, efficiency index and valuation index. Net income increased 2,141.15% from -$192 to $3.92M, earnings per share increased from -$0.0041 to $0.08, and EBIT increased 220.36% from -$2.92M to $3.52M.
D
Sell
8/13/2020Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C+ on 8/13/2020 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 139.06% from $7.48M to -$2.92M, earnings per share declined from $0.08 to -$0.0041, and net income declined 104.86% from $3.95M to -$192.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C+ on 8/13/2020 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 139.06% from $7.48M to -$2.92M, earnings per share declined from $0.08 to -$0.0041, and net income declined 104.86% from $3.95M to -$192.
C
Hold
7/10/2020Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C+ from C on 7/10/2020 due to a noticeable increase in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C+ from C on 7/10/2020 due to a noticeable increase in the total return index and volatility index.
C
Hold
6/2/2020Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 6/2/2020 due to a major increase in the growth index, volatility index and solvency index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 6/2/2020 due to a major increase in the growth index, volatility index and solvency index.
C
Hold
5/15/2020Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C- from C on 5/15/2020 due to a decline in the volatility index and total return index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C- from C on 5/15/2020 due to a decline in the volatility index and total return index.
C
Hold
4/9/2020Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 4/9/2020 due to an increase in the volatility index and total return index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 4/9/2020 due to an increase in the volatility index and total return index.
C
Hold
3/25/2020Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C- from C on 3/25/2020 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0277 to -$0.026, and EBIT declined 110.15% from $2.4M to -$244.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C- from C on 3/25/2020 due to a substantial decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0277 to -$0.026, and EBIT declined 110.15% from $2.4M to -$244.
C
Hold
10/22/2019Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C from C+ on 10/22/2019 due to a decline in the volatility index, total return index and valuation index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C from C+ on 10/22/2019 due to a decline in the volatility index, total return index and valuation index.
C
Hold
10/7/2019Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C+ from C on 10/7/2019 due to an increase in the volatility index and valuation index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C+ from C on 10/7/2019 due to an increase in the volatility index and valuation index.
C
Hold
8/13/2019Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from D+ on 8/13/2019 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 5,405.41% from $868 to $47.79M, earnings per share increased from $0.0186 to $0.96, and operating cash flow increased 1,532.77% from -$3.61M to $51.72M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from D+ on 8/13/2019 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 5,405.41% from $868 to $47.79M, earnings per share increased from $0.0186 to $0.96, and operating cash flow increased 1,532.77% from -$3.61M to $51.72M.
D
Sell
6/3/2019Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C- on 6/3/2019 due to a decline in the total return index, volatility index and solvency index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C- on 6/3/2019 due to a decline in the total return index, volatility index and solvency index.
C
Hold
5/15/2019Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 5/15/2019 due to a noticeable increase in the growth index, efficiency index and volatility index. Total capital increased 6.75% from $414.57M to $442.56M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 5/15/2019 due to a noticeable increase in the growth index, efficiency index and volatility index. Total capital increased 6.75% from $414.57M to $442.56M.
D
Sell
5/1/2019Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C- on 5/1/2019 due to a noticeable decline in the total return index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C- on 5/1/2019 due to a noticeable decline in the total return index.
C
Hold
3/29/2019Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C- from C on 3/29/2019 due to a major decline in the growth index, efficiency index and total return index. Operating cash flow declined 39.69% from $15.78M to $9.52M, EBIT declined 39.41% from $2.55M to $1.55M, and earnings per share declined from $0.05 to $0.0379.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C- from C on 3/29/2019 due to a major decline in the growth index, efficiency index and total return index. Operating cash flow declined 39.69% from $15.78M to $9.52M, EBIT declined 39.41% from $2.55M to $1.55M, and earnings per share declined from $0.05 to $0.0379.
C
Hold
1/11/2019Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 1/11/2019 due to a major increase in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 1/11/2019 due to a major increase in the total return index and volatility index.
C
Hold
11/14/2018Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 11/14/2018 due to a large increase in the growth index, total return index and efficiency index. Operating cash flow increased 248.14% from $4.53M to $15.78M, EBIT increased 189.25% from -$2.86M to $2.55M, and net income increased 185.63% from -$2.79M to $2.39M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 11/14/2018 due to a large increase in the growth index, total return index and efficiency index. Operating cash flow increased 248.14% from $4.53M to $15.78M, EBIT increased 189.25% from -$2.86M to $2.55M, and net income increased 185.63% from -$2.79M to $2.39M.
D
Sell
8/14/2018Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to D+ from D on 8/14/2018 due to an increase in the growth index, volatility index and efficiency index. EBIT increased 71.19% from -$9.92M to -$2.86M, earnings per share increased from -$0.16 to -$0.06, and net income increased 61.5% from -$7.25M to -$2.79M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to D+ from D on 8/14/2018 due to an increase in the growth index, volatility index and efficiency index. EBIT increased 71.19% from -$9.92M to -$2.86M, earnings per share increased from -$0.16 to -$0.06, and net income increased 61.5% from -$7.25M to -$2.79M.
D
Sell
5/15/2018Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D from D+ on 5/15/2018 due to a substantial decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.0298 to -$0.16, net income declined 593.6% from $1.47M to -$7.25M, and EBIT declined 496.03% from -$1.66M to -$9.92M.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D from D+ on 5/15/2018 due to a substantial decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.0298 to -$0.16, net income declined 593.6% from $1.47M to -$7.25M, and EBIT declined 496.03% from -$1.66M to -$9.92M.
D
Sell
5/10/2018Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C- on 5/10/2018 due to a decline in the volatility index and total return index.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C- on 5/10/2018 due to a decline in the volatility index and total return index.
C
Hold
3/16/2018Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 3/16/2018 due to a noticeable increase in the growth index, total return index and efficiency index. Net income increased 738.86% from $175 to $1.47M, earnings per share increased from $0.0036 to $0.0298, and operating cash flow increased 295.02% from $2.47M to $9.77M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 3/16/2018 due to a noticeable increase in the growth index, total return index and efficiency index. Net income increased 738.86% from $175 to $1.47M, earnings per share increased from $0.0036 to $0.0298, and operating cash flow increased 295.02% from $2.47M to $9.77M.
D
Sell
8/11/2017Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C on 8/11/2017 due to a large decline in the growth index, total return index and valuation index. Operating cash flow declined 79.58% from $22.4M to $4.57M.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C on 8/11/2017 due to a large decline in the growth index, total return index and valuation index. Operating cash flow declined 79.58% from $22.4M to $4.57M.
C
Hold
7/6/2017Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 7/6/2017 due to a noticeable increase in the total return index and volatility index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from C- on 7/6/2017 due to a noticeable increase in the total return index and volatility index.
C
Hold
5/12/2017Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 5/12/2017 due to a major increase in the growth index. Earnings per share increased from -$0.065 to $0.0194, EBIT increased 74.41% from -$4.84M to -$1.24M, and operating cash flow increased 59.92% from $14.01M to $22.4M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C- from D+ on 5/12/2017 due to a major increase in the growth index. Earnings per share increased from -$0.065 to $0.0194, EBIT increased 74.41% from -$4.84M to -$1.24M, and operating cash flow increased 59.92% from $14.01M to $22.4M.
D
Sell
5/1/2017Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C- on 5/1/2017 due to a large decline in the valuation index, growth index and efficiency index. EBIT declined 183.51% from $5.8M to -$4.84M, earnings per share declined from $0.08 to -$0.065, and net income declined 170.49% from $3.89M to -$2.74M.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to D+ from C- on 5/1/2017 due to a large decline in the valuation index, growth index and efficiency index. EBIT declined 183.51% from $5.8M to -$4.84M, earnings per share declined from $0.08 to -$0.065, and net income declined 170.49% from $3.89M to -$2.74M.
C
Hold
3/15/2017Downgrade
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C- from C on 3/15/2017 due to a large decline in the growth index and volatility index. Operating cash flow declined 86.08% from $9.33M to $1.3M, earnings per share declined from $0.15 to $0.08, and EBIT declined 44.49% from $10.44M to $5.8M.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to C- from C on 3/15/2017 due to a large decline in the growth index and volatility index. Operating cash flow declined 86.08% from $9.33M to $1.3M, earnings per share declined from $0.15 to $0.08, and EBIT declined 44.49% from $10.44M to $5.8M.
C
Hold
8/11/2016Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from D+ on 8/11/2016 due to a substantial increase in the growth index, efficiency index and valuation index. Earnings per share increased from $0.05 to $0.15, net income increased 177.02% from $2.49M to $6.9M, and EBIT increased 122.59% from $4.69M to $10.44M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to C from D+ on 8/11/2016 due to a substantial increase in the growth index, efficiency index and valuation index. Earnings per share increased from $0.05 to $0.15, net income increased 177.02% from $2.49M to $6.9M, and EBIT increased 122.59% from $4.69M to $10.44M.
D
Sell
1/4/2016Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to D+ from D on 1/4/2016 due to an increase in the solvency index and valuation index. Debt to equity declined from 0.17 to 0.16, and the quick ratio increased from 1.44 to 1.44.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to D+ from D on 1/4/2016 due to an increase in the solvency index and valuation index. Debt to equity declined from 0.17 to 0.16, and the quick ratio increased from 1.44 to 1.44.
D
Sell
7/1/2015Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to D from D- on 7/1/2015 due to a large increase in the growth index, solvency index and total return index. EBIT increased 4.53% from -$6.95M to -$7.26M, and total revenue increased 1.81% from $55.88M to $56.89M.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to D from D- on 7/1/2015 due to a large increase in the growth index, solvency index and total return index. EBIT increased 4.53% from -$6.95M to -$7.26M, and total revenue increased 1.81% from $55.88M to $56.89M.
D
Sell
3/2/2015Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to D- from E+ on 3/2/2015 due to a noticeable increase in the volatility index and total return index.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to D- from E+ on 3/2/2015 due to a noticeable increase in the volatility index and total return index.
E
Sell
12/1/2014Upgraded
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to E+ from E on 12/1/2014 due to a substantial increase in the total return index, solvency index and volatility index. The quick ratio increased from 1.54 to 1.66, and debt to equity declined from 0.19 to 0.18.
Amphastar Pharmaceuticals, Inc. (AMPH) was upgraded to E+ from E on 12/1/2014 due to a substantial increase in the total return index, solvency index and volatility index. The quick ratio increased from 1.54 to 1.66, and debt to equity declined from 0.19 to 0.18.
E
Sell
9/19/2014None
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to E from U on 09/19/2014.
Amphastar Pharmaceuticals, Inc. (AMPH) was downgraded to E from U on 09/19/2014.
NASDAQ
03/07/2025 3:00PM Eastern
Quotes delayed
